Floatz logo

Demcizumab

Nonsquamous Nonsmall Cell Neoplasm of Lung

OncoMed Pharmaceuticals, Inc.monoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Nonsquamous Nonsmall Cell Neoplasm of Lung cohort.

Asset / SponsorPhaseRating
Carboplatin
Arcus Biosciences, Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Intergroupe Francophone de Cancerologie Thoracique
Phase 2BB
Irinotecan
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
(+)-VINCRISTINE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
Adv/Hsv-Tk
Eric Bernicker, MD
Phase 2CCC

View all 20 →

Same molecule, other indications

Demcizumab is also rated in:

pancreatic neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
Locally Advanced or Metastatic Solid TumorsDormant
CC
Indicative ·
44 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →